Ashkan Golshani: A Step Closer to Developing a Therapeutic Against Platelet-type von Willebrand Disease
Ashkan Golshani, Professor at Carleton University, Co-founder of Designed Biologics, shared on LinkedIn:
”A step closer to developing a therapeutic against Platelet-type von Willebrand Disease (PT-VWD).
I am extremely proud of my team for developing the first-ever drug candidate against PT-VWD, a rare bleeding disorder (published in Blood Advances).
Using our state-of-the-art artificial intelligence-based drug development platform, my lab has developed a peptide that can reverse the phenotype of the mutant protein causing PT-VWD to its wild-type state.
Many thanks to my wonderful collaborators in this project Dr. Maha Othman and Paolo Gresele and all the members of my laboratory, past and present, especially Thomas Kazmirchuk, who spearheaded this project in my lab.
This work provides additional evidence for the applicability of our proprietary AI technology in developing novel therapeutics and diagnostics, moving us closer to replacing traditional monoclonal antibody development with AI-assisted method.”
Read the full article in Blood Advances.
Article: Developing an AI-Generated Peptide Targeting Platelet-type von Willebrand Disease
Authors: Thomas David Daniel Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-gafari, Sarah Takallou, William G Willmore, Frank Dehne, Paolo Gresele, Maha Othman, Ashkan Golshani
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand